Citigroup’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $217K | Sell |
14,845
-13
| -0.1% | -$207 | ﹤0.01% | 3971 |
|
|
2025
Q4 | $114K | Buy |
14,858
+10,910
| +276% | +$86K | ﹤0.01% | 4265 |
|
|
2025
Q3 | $29.1K | Sell |
3,948
-19,724
| -83% | -$101K | ﹤0.01% | 4675 |
|
|
2025
Q2 | $94.7K | Buy |
23,672
+22,151
| +1,456% | +$80.6K | ﹤0.01% | 4429 |
|
|
2025
Q1 | $4.84K | Sell |
1,521
-46,701
| -97% | -$220K | ﹤0.01% | 5275 |
|
|
2024
Q4 | $258K | Sell |
48,222
-74,636
| -61% | -$557K | ﹤0.01% | 4251 |
|
|
2024
Q3 | $649K | Buy |
+122,858
| New | +$441K | ﹤0.01% | 3565 |
|
|
2022
Q4 | – | Sell |
-526
| Closed | – | – | 5801 |
|
|
2022
Q3 | $0 | Sell |
526
-158
| -23% | -$151 | ﹤0.01% | 5898 |
|
|
2022
Q2 | $1K | Sell |
684
-1,358
| -67% | -$1.67K | ﹤0.01% | 5997 |
|
|
2022
Q1 | $3K | Buy |
2,042
+639
| +46% | +$1.17K | ﹤0.01% | 5950 |
|
|
2021
Q4 | $3K | Buy |
1,403
+1,376
| +5,096% | +$5.34K | ﹤0.01% | 5708 |
|
|
2021
Q3 | $0 | Hold |
27
| – | – | ﹤0.01% | 5834 |
|
|
2021
Q2 | $0 | Hold |
27
| – | – | ﹤0.01% | 6163 |
|
|
2021
Q1 | $0 | Hold |
27
| – | – | ﹤0.01% | 6445 |
|
|
2020
Q4 | $0 | Hold |
27
| – | – | ﹤0.01% | 7399 |
|
|
2020
Q3 | $0 | Hold |
27
| – | – | ﹤0.01% | 7468 |
|
|
2020
Q2 | $0 | Sell |
27
-1,780
| -99% | -$5.26K | ﹤0.01% | 7556 |
|
|
2020
Q1 | $4K | Buy |
1,807
+1,780
| +6,593% | +$7.23K | ﹤0.01% | 7305 |
|
|
2019
Q4 | $0 | Sell |
27
-1,537
| -98% | -$5.38K | ﹤0.01% | 7687 |
|
|
2019
Q3 | $5K | Hold |
1,564
| – | – | ﹤0.01% | 7320 |
|
|
2019
Q2 | $6K | Sell |
1,564
-2,182
| -58% | -$8.55K | ﹤0.01% | 7430 |
|
|
2019
Q1 | $15K | Buy |
3,746
+97
| +3% | +$409 | ﹤0.01% | 7084 |
|
|
2018
Q4 | $14K | Buy |
3,649
+640
| +21% | +$4.36K | ﹤0.01% | 7031 |
|
|
2018
Q3 | $26K | Buy |
+3,009
| New | +$30.1K | ﹤0.01% | 6956 |
|
|
2018
Q2 | – | Sell |
-1,547
| Closed | -$17K | – | 7617 |
|
|
2018
Q1 | $17K | Buy |
1,547
+1,412
| +1,046% | +$13.4K | ﹤0.01% | 6823 |
|
|
2017
Q4 | $1K | Buy |
135
+134
| +13,400% | +$1.72K | ﹤0.01% | 7464 |
|
|
2017
Q3 | $0 | Sell |
1
-55
| -98% | -$761 | ﹤0.01% | 7272 |
|
|
2017
Q2 | $1K | Sell |
56
-90
| -62% | -$961 | ﹤0.01% | 7128 |
|
|
2017
Q1 | $3K | Sell |
146
-4,200
| -97% | -$65.8K | ﹤0.01% | 6915 |
|
|
2016
Q4 | $62K | Buy |
4,346
+3,077
| +242% | +$46.8K | ﹤0.01% | 6041 |
|
|
2016
Q3 | $20K | Sell |
1,269
-61
| -5% | -$879 | ﹤0.01% | 6206 |
|
|
2016
Q2 | $19K | Buy |
1,330
+830
| +166% | +$11.2K | ﹤0.01% | 6186 |
|
|
2016
Q1 | $7K | Buy |
+500
| New | +$7.17K | ﹤0.01% | 6897 |
|
Other funds holding CRVS
O
ASP
VCM
VC
DTC
Citigroup's CRVS Position: Q1 2026 in Review
Citigroup reduced its Corvus Pharmaceuticals (CRVS) stake by 0.09% in Q1 2026, selling an estimated $207 and leaving 14,845 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.
Citigroup first reported a position in CRVS in Q1 2016 and has held it in 33 quarters since. The position peaked at $649K in Q3 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.
- Citigroup held 14,845 shares of Corvus Pharmaceuticals worth $217K as of Q1 2026.
- Citigroup sold 13 Corvus Pharmaceuticals shares in Q1 2026, an estimated $207.
- Corvus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3971 holding.
- Citigroup first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 33 quarters since.
- Citigroup's Corvus Pharmaceuticals position peaked at $649K in Q3 2024.
- 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.